TYRA-300 for children with achondroplasia (BEACH301)
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This study tests an experimental oral medication (TYRA-300) for children with achondroplasia, a common form of dwarfism. The goal is to see if it can safely improve growth in children whose growth plates are still open.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 3 and 10 years old.
- Your child must have a confirmed genetic diagnosis of achondroplasia (the FGFR3 G380R change).
- Your child's bone growth plates must still be open, as shown by an X-ray.
- Your child must be able to stand, walk, and take medicine by mouth.
- Your child cannot have had limb lengthening surgery before or plan to have it during the study.
- Your child cannot have certain eye conditions or take specific medications that might interfere with the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medicine (ABSK061) to see if it can safely improve growth in children with achondroplasia. It is a phase 1/2 trial, meaning it is early research to find the right dose and check for benefits.
This trial tests a new medicine for children with achondroplasia (a common form of dwarfism). It aims to see if the drug can improve growth. The study is for children aged 2.5 to under 11 years old who have not started puberty and can walk without help.
This trial tests an oral medication called infigratinib to see if it can help young children with achondroplasia. It is for children under 3 years old who have a confirmed genetic diagnosis.
This trial tests a new weekly injection called TransCon CNP for infants with achondroplasia (the most common form of dwarfism). The goal is to see if it can help children grow better than a placebo (a shot with no medicine).
This trial tests a new medicine, BMN 333, against an existing one (vosoritide) to see if it helps children with achondroplasia grow. It's for kids who haven't used these treatments before.
This trial looks at how safe and effective weekly under-the-skin (subcutaneous) TransCon CNP is for children and teens with achondroplasia over the long term. You may be considered if your child has already finished a previous TransCon CNP study and can follow weekly injection and follow-up visits.
Hear when a new Achondroplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.